Payment overview · 2025
General Payments
$77.49
4 reported records · 3 companies
Healthcare provider profile · identity verified
Reginald Patrick Segar, MD
Allopathic & Osteopathic Physicians|Family Medicine · EUNICE, LA · NPI 1720057417
Verified facts
What the public records show
CMS Open Payments records show Reginald Patrick Segar, MD received $77.49 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 49.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lumigan by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.66 | 49.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.23 | 26.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.60 | 24.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $77.49 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 141 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
83 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
141 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 656 | 116 |
| Atorvastatin Calcium | Atorvastatin Calcium | 412 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 371 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 365 | 68 |
| Metformin Hcl | Metformin Hcl | 345 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 302 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 296 | 45 |
| Omeprazole | Omeprazole | 269 | 40 |
| Losartan Potassium | Losartan Potassium | 258 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 257 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 237 | 32 |
| Tramadol Hcl | Tramadol Hcl | 220 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 203 | 31 |
| Gabapentin | Gabapentin | 182 | 29 |
| Diazepam | Diazepam | 172 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 28 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 168 | 19 |
| Furosemide | Furosemide | 159 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 27 |
| Prednisone | Prednisone | 153 | 92 |
| Zolpidem Tartrate | Zolpidem Tartrate | 148 | 23 |
| Allopurinol | Allopurinol | 147 | 31 |
| Clonazepam | Clonazepam | 146 | 24 |
| Potassium Chloride | Potassium Chloride | 142 | 22 |
| Farxiga | Dapagliflozin Propanediol | 141 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 16 |
| Alprazolam | Alprazolam | 134 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 131 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 29 |
| Pregabalin | Pregabalin | 128 | 24 |
| Sertraline Hcl | Sertraline Hcl | 127 | 20 |
| Trazodone Hcl | Trazodone Hcl | 126 | 21 |
| Jardiance | Empagliflozin | 123 | 17 |
| Atenolol | Atenolol | 121 | 19 |
| Eliquis | Apixaban | 118 | 14 |
| Benazepril Hcl | Benazepril Hcl | 112 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 110 | 46 |
| Valsartan | Valsartan | 110 | 25 |
| Ezetimibe | Ezetimibe | 108 | 19 |
| Famotidine | Famotidine | 108 | 21 |
| Simvastatin | Simvastatin | 107 | 17 |
| Azelastine Hcl | Azelastine Hcl | 103 | 54 |
| Diclofenac Sodium | Diclofenac Sodium | 101 | 23 |
| Lovastatin | Lovastatin | 100 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 19 |
| Finasteride | Finasteride | 94 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 18 |
| Ozempic | Semaglutide | 85 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 38 |
| Linzess | Linaclotide | 83 | 14 |
| Alendronate Sodium | Alendronate Sodium | 81 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 75 | 12 |
| Lisinopril | Lisinopril | 74 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 11 |
| Clonidine Hcl | Clonidine Hcl | 72 | 16 |
| Meloxicam | Meloxicam | 72 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 72 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 64 | 51 |
| Estradiol | Estradiol | 61 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | suppressed |
| Fenofibrate | Fenofibrate | 55 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 55 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | suppressed |
| Carvedilol | Carvedilol | 48 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 48 | suppressed |
| Levofloxacin | Levofloxacin | 44 | 34 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 44 | 35 |
| Mupirocin | Mupirocin | 43 | 28 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Glipizide | Glipizide | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 37 | 19 |
| Methylprednisolone | Methylprednisolone | 37 | 28 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 21 |
| Azithromycin | Azithromycin | 30 | 27 |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 14 |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | 15 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 16 |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Digoxin | Digoxin | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Famciclovir | Famciclovir | 15 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Lumigan | Bimatoprost | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $77.49 · 4 records | AstraZeneca Pharmaceuticals LP | BREZTRI, FARXIGA, QULIPTA, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error